HERCULES, Calif., July 31, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the ...
Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin ...
Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here. The fund returned -0.33% in the third ...
Bio-Rad Laboratories, Inc.’s BIO Clinical Diagnostics business is back to its usual growth trajectory post-pandemic while maintaining a strong market position worldwide for key platforms. The ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced that MicroVal, the international certification organization for the validation ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz ...
Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt ...
Normal Schwartz has been the Chief Executive Officer or CEO, President, and Chairman of Bio-Rad laboratories since 2003. Meet Bio-Rad laboratories chief executive officer or CEO, Norman Schwartz. The ...
A federal jury Monday awarded the former general counsel of Bio-Rad Laboratories $8 million in back pay and damages — which will increase to $11 million — for whistleblower retaliation involving ...
Bio-Rad Labs (BIO) has delivered a -11.12% change over the past year, with a 52-week range between 211.43 and 373.69. What Is the Average Daily Trading Volume of Bio-Rad Labs (BIO)? The average daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback